Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials

BACKGROUND: Several candidate vaccines to prevent COVID-19 disease have entered large-scale phase 3 placebo-controlled randomized clinical trials and some have demonstrated substantial short-term efficacy. Efficacious vaccines should, at some point, be offered to placebo participants, which will occ...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:medRxiv
Autors principals: Follmann, Dean, Fintzi, Jonathan, Fay, Michael P., Janes, Holly E., Baden, Lindsey, Sahly, Hana El, Fleming, Thomas R., Mehrotra, Devan V., Carpp, Lindsay N., Juraska, Michal, Benkeser, David, Donnell, Deborah, Fong, Youyi, Han, Shu, Hirsch, Ian, Huang, Ying, Huang, Yunda, Hyrien, Ollivier, Luedtke, Alex, Carone, Marco, Nason, Martha, Vandebosch, An, Zhou, Honghong, Cho, Iksung, Gabriel, Erin, Kublin, James G., Cohen, Myron S., Corey, Lawrence, Gilbert, Peter B., Neuzil, Kathleen M.
Format: Artigo
Idioma:Inglês
Publicat: Cold Spring Harbor Laboratory 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7745130/
https://ncbi.nlm.nih.gov/pubmed/33336213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.12.14.20248137
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars